Suggested remit: To appraise the clinical and cost effectiveness of hydromethylthionine mesylate within its marketing authorisation for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6343

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors TauRx Therapeutics (hydromethylthionine mesylate)
Others Department of Health and Social Care
  NHS England
Patient carer groups Alzheimer’s Research UK
  Alzheimer's Society
  Dementia UK
Professional groups Association of British Neurologists
  College of Mental Health Pharmacy
  Royal College of Physicians
  Royal College of Psychiatrists
Associated public health groups None
Comparator companies Eisai (donepezil, lecanemab) (confidentiality agreement signed, participating)
  Eli Lilly and Company (donanemab) (confidentiality agreement signed, participating)
  Novartis Pharmaceuticals (rivastigmine) (confidentiality agreement signed, participating)
  Accord-UK (donepezil, galantamine, memantine) (confidentiality agreement not signed, not participating)
  Aspire Pharma (galantamine) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma – Milpharm (donepezil, galantamine) (confidentiality agreement not signed, not participating)
  Cipla (donepezil) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (galantamine, memantine, rivastigmine) (confidentiality agreement not signed, not participating)
  Fontus Health (galantamine) (confidentiality agreement not signed, not participating)
  Genus Pharmaceuticals (memantine) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals (memantine) (confidentiality agreement not signed, not participating)
  Kent Pharma (rivastigmine) (confidentiality agreement not signed, not participating)
  Krka UK (memantine, rivastigmine) (confidentiality agreement not signed, not participating)
  Lundbeck (memantine) (confidentiality agreement not signed, not participating)
  Lupin Healthcare (memantine) (confidentiality agreement not signed, not participating)
  Mylan (donepezil, memantine, rivastigmine) (confidentiality agreement not signed, not participating)
  Ranbaxy, a Sun Pharmaceutical Company (donepezil) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (donepezil, memantine, rivastigmine) (confidentiality agreement not signed, not participating)
  Sandoz (galantamine, rivastigmine) (confidentiality agreement not signed, not participating)
  Takeda (galantamine) (confidentiality agreement not signed, not participating)
  Thame Laboratories (galantamine) (confidentiality agreement not signed, not participating)
  Zentiva (memantine, galantamine) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups National Hospital for Neurology and Neurosurgery

Timeline

Key events during the development of the guidance:

Date Update
19 December 2024 The committee meeting planned for 12 February 2025 will be rescheduled and the timelines for this appraisal will be revised to ensure they align with regulatory timings. We will provide a further update when it is available.
10 July 2024 Invitation to participate
01 May 2024 - 31 May 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6343
01 May 2024 In progress. Scoping commencing
14 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual